Safety and Effectiveness of Laparoscopic Surgery for Gastric Gastrointestinal Stromal Tumors 5cm and Larger
A Multicenter Prospective Cohort Study
Led by Fujian Medical University · Updated on 2023-07-10
194
Participants Needed
1
Research Sites
156 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are investigating the safety of laparoscopic surgery to remove gastric gastrointestinal stromal tumors GIST that are 5 cm or larger. This prospective, multicenter cohort study aims to compare the clinical outcomes of laparoscopic resection of large gastric GISTs with those of smaller tumors less than 5 cm. The main focus is to evaluate overall postoperative complications within 30 days after surgery or upon discharge if the hospital stay is longer.
The study involves two groups patients undergoing laparoscopic removal of gastric GISTs 5 cm or larger, and those with tumors smaller than 5 cm receiving the same procedure. The laparoscopic approach is expected to achieve complete tumor removal R0 resection. Various postoperative measures will be observed, including rates of complications during and after surgery, conversion to open surgery, surgical margin status, and changes in blood tests such as white blood cell count, hemoglobin, and C-reactive protein.
Participants will be closely monitored after surgery through assessments of recovery milestones like time to first movement, bowel function, diet progression, and duration of hospital stay. Long-term outcomes including 3-year overall survival, disease-free survival, and recurrence patterns will also be recorded. The total follow-up spans up to 36 months, with detailed postoperative evaluations conducted up to 30 days and blood tests monitored before and after surgery at specified intervals.
CONDITIONS
Brief Title
A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors
Research Team
P
Ping Li, MD,PhD
L
Linghua Wei
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Primary gastric lesion diagnosed as gastric GIST by endoscopic biopsy or suspected by endoscopy, ultrasound, CT, or MRI, confirmed by postoperative pathology
Patient gives informed consent and agrees to laparoscopic resection
Expected to achieve complete tumor removal (R0 resection) by laparoscopy
Performance status: ECOG score 2 or less, ASA score I-III before surgery
You will not qualify if you...
Women who are pregnant or breastfeeding
Severe mental disorders
History of upper abdominal surgery except laparoscopic gallbladder removal
History of gastric surgery except endoscopic submucosal dissection or mucosal resection for gastric cancer
History of other cancers within the past five years
History of unstable angina or heart attack within the past six months
History of stroke within the past six months
Continuous corticosteroid use within one month
Need for simultaneous surgery for other diseases
Emergency surgery due to complications from gastric cancer such as bleeding, obstruction, or perforation
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Surgery and Immediate Post-operative Care
Duration - Hospital stay up to 30 days
Participants undergo laparoscopic resection of gastric gastrointestinal stromal tumors followed by immediate post-operative monitoring.
Daily visits during hospital stay
Post-operative Follow-up
Duration - Up to 36 months
Participants are followed up to monitor recovery and assess overall morbidity, survival, and recurrence.
Scheduled visits up to 36 months after surgery
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Phase 2 Study of 5 Years of Adjuvant Imatinib Treatment for High-Risk Gastrointestinal Stromal Tumor After Surgery
Safety and Effectiveness of Laparoscopic Surgery for Gastric Gastrointestinal Stromal Tumors 5cm and Larger
A Multicenter Prospective Cohort Study
Observational Study on Avapritinib Treatment in Adults with Metastatic or Unresectable Gastrointestinal Stromal Tumors
Phase 1 Study of NN3201, a c-Kit Targeting Antibody-Drug Combination, for Advanced or Metastatic Solid Tumors Expressing c-Kit
Study Comparing Apatinib Mesylate to Standard Second-line TKIs for Advanced Gastrointestinal Stromal Tumors After First-line Treatment Failure
Phase II Study Comparing In-Person Physician Monitoring Versus Remote Nurse Monitoring
for Personalized Post-Treatment Surveillance in Adults With Rare Tumors
Avapritinib Treatment for Unresectable or Recurrent Metastatic Gastrointestinal Stromal Tumors with Non-exon18 PDGFRA Mutations
A Real-World Observational Study
Study of Drug Holiday Based on MRD Detection in High-Risk Gastrointestinal Stromal Tumor Patients
Monitoring Recurrence and Treatment Outcomes After Surgery and Imatinib Therapy
Study of Sunitinib and Regorafenib Guided by KIT Gene Mutations for Treating Gastrointestinal Stromal Tumors
Study of Radiotherapy with Ripretinib for Treating Adults with Unresectable Advanced Gastrointestinal Stromal Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Impact of the introduction of laparoscopic wedge resection as a surgical option for suspected small/medium-sized gastrointestinal stromal tumors of the stomach on perioperative and oncologic outcomes.
Early experience of laparoscopic resection and comparison with open surgery for gastric gastrointestinal stromal tumor: a multicenter retrospective study.